Expectations for Novartis' canakinumab as an oncology therapy were already fading fast, and have now been nixed after a third phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its ...

These findings may lead to a new understanding of the use of colchicine in CVD treatment. The monoclonal antibody canakinumab can neutralize IL-1β directly. Canakinumab’s Canakinumab Anti-Inflammatory ...

Canakinumab, MCC950, Colchicine, Interleukin-37 and Interferons) targeting inflammasomes or related pathways. They specially emphasized that IL-1β participated in multiple cellular events in both ...